NO20022441L - Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse - Google Patents

Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse

Info

Publication number
NO20022441L
NO20022441L NO20022441A NO20022441A NO20022441L NO 20022441 L NO20022441 L NO 20022441L NO 20022441 A NO20022441 A NO 20022441A NO 20022441 A NO20022441 A NO 20022441A NO 20022441 L NO20022441 L NO 20022441L
Authority
NO
Norway
Prior art keywords
methods
treating lupus
preparations
antibody affinity
screening methods
Prior art date
Application number
NO20022441A
Other languages
English (en)
Other versions
NO20022441D0 (no
Inventor
Matthew D Linnik
Patricia A Mcneely
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of NO20022441D0 publication Critical patent/NO20022441D0/no
Publication of NO20022441L publication Critical patent/NO20022441L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen tilveiebringer fremgangsmåter til påvisning av individer som er egnet for behandling av lupus og fremgangsmåter til overvåking av behandling basert på måling av antistoffaffiniteter, så vel som behandling av lupus basert på måling av antistoffaffiniteter. Behandlingen medfører administrering av et konjugat som omfatter et ikke-immunogent valensplattformmolekyl og minst to dobbelttrådete DNA epitoper, slik som DNA molekyler som binder til anti-dsDNA antistoffer fra pasienten.
NO20022441A 1999-11-28 2002-05-23 Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse NO20022441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16771699P 1999-11-28 1999-11-28
PCT/US2000/042307 WO2001041813A2 (en) 1999-11-28 2000-11-28 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

Publications (2)

Publication Number Publication Date
NO20022441D0 NO20022441D0 (no) 2002-05-23
NO20022441L true NO20022441L (no) 2002-07-09

Family

ID=22608518

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022441A NO20022441L (no) 1999-11-28 2002-05-23 Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse

Country Status (11)

Country Link
US (2) US7081242B1 (no)
EP (1) EP1233791A2 (no)
JP (1) JP2003516526A (no)
KR (1) KR20020059808A (no)
CN (2) CN1399562A (no)
AU (1) AU783282C (no)
CA (1) CA2391944A1 (no)
HK (1) HK1045944A1 (no)
MX (1) MXPA02005236A (no)
NO (1) NO20022441L (no)
WO (1) WO2001041813A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
US20060229270A1 (en) * 2005-03-10 2006-10-12 La Jolla Pharmaceutical Company Methods of treating proteinuria by reducing double-stranded DNA antibodies
US8492347B2 (en) * 2007-10-17 2013-07-23 The Regents Of The University Of California Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
CN102477079A (zh) * 2010-11-24 2012-05-30 中国人民解放军军事医学科学院基础医学研究所 一种新型多肽在系统性红斑狼疮诊断中的应用
WO2012116210A2 (en) * 2011-02-23 2012-08-30 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus
CN116514921A (zh) * 2023-04-26 2023-08-01 西安交通大学 一种靶向抗双链dna抗体的d型多肽及其在制备治疗系统性红斑狼疮的药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5391785A (en) 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
IE922292A1 (en) 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
EP1808183A3 (en) 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
ATE245030T1 (de) 1994-02-28 2003-08-15 Univ Virginia Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
EP0974550B1 (en) 1997-04-11 2004-08-11 Chiyoda Corporation Catalyst for preparation of synthesis gas and process for preparing carbon monoxide
ATE393912T1 (de) 1998-02-04 2008-05-15 Invitrogen Corp Microarrays und ihre verwendungen
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
JP2002524533A (ja) 1998-09-10 2002-08-06 ザ ユニヴァーシティー オブ ヴァージニア パテント ファウンデーション 癌細胞に診断薬及び治療薬をデリバリーするためのＣ３ｂ（ｉ）に対する抗体
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
CA2353620A1 (en) 1998-12-09 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2376057A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
WO2001045669A1 (en) 1999-12-23 2001-06-28 Elusys Therapeutics, Inc. Therapeutic use of particles displaying pathogen-specific binding moieties
WO2001080883A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
CN1511041A (zh) 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
US20030114405A1 (en) 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
AU2003303524A1 (en) 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals

Also Published As

Publication number Publication date
AU783282C (en) 2006-04-06
US7081242B1 (en) 2006-07-25
HK1045944A1 (zh) 2002-12-20
WO2001041813A3 (en) 2002-01-03
AU783282B2 (en) 2005-10-06
KR20020059808A (ko) 2002-07-13
AU3970201A (en) 2001-06-18
CA2391944A1 (en) 2001-06-14
MXPA02005236A (es) 2004-03-19
US20060142229A1 (en) 2006-06-29
JP2003516526A (ja) 2003-05-13
CN101422614A (zh) 2009-05-06
CN1399562A (zh) 2003-02-26
NO20022441D0 (no) 2002-05-23
WO2001041813A2 (en) 2001-06-14
EP1233791A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
Soskine et al. An engineered ClyA nanopore detects folded target proteins by selective external association and pore entry
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
DE69936927D1 (de) Polyspezifische bindemoleküle und deren verwendung
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
NO20005694D0 (no) Spesifikke bindingsmolekyler for scintigrafi, konjugater som inneholder disse og terapeutisk metode for behandling av angiogenese
NO995458L (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
DE60142614D1 (de) Inität
DE602005021072D1 (de) Adzyme und deren verwendungen
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
Okun et al. Affinity capillary electrophoresis for the assessment of complex formation between viruses and monoclonal antibodies
WO2003055917A3 (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
PT1214600E (pt) Determinacao de proteinas de ligacao a adrenomedulina
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
DK1692181T3 (da) Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin
Wragg et al. Unveiling the mechanisms of aquaglyceroporin‐3 water and glycerol permeation by metadynamics
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2001041813A3 (en) Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
HK1052532A1 (zh) α(2)巨球蛋白受體作為熱沖擊蛋白受體及其用途
ATE250966T1 (de) Adsoptionschromatographie
WO2000002582A3 (en) Treatment of celiac disease with interleukin-15 antagonists
Hernaiz et al. Characterization of heparin binding by a peptide from amyloid P component using capillary electrophoresis, surface plasmon resonance and isothermal titration calorimetry

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application